<DOC>
	<DOC>NCT02767479</DOC>
	<brief_summary>Patients infected with H. pylori are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and CAM 200 mg bid. Eradication rates are compared. Patients who have ever failed in eradication by CAM-based regimen are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and MNZ 250 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and MNZ 250 mg bid.</brief_summary>
	<brief_title>Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori</brief_title>
	<detailed_description>Patients infected with H. pylori are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and CAM 200 mg bid. Eradication rates are compared. Patients who have ever failed in eradication by CAM-based regimen are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and MNZ 250 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and MNZ 250 mg bid. CYP2C19 genotypes and susceptibility to CAM are genetically measured. Other factors are also analyzed with reference to eradication rates.</detailed_description>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Patients infected with H. pylori who can undergo the eradication therapy Patients with severe other disorders, cannot undergo eradication therapy, refuses to participate to the study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>eradication rates</keyword>
	<keyword>rabeprazole</keyword>
	<keyword>esomeprazole</keyword>
</DOC>